# US 2024/0254188 A1 · Cd33 specific chimeric antigen receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254188 A1
- Document ID: US20240254188A1
- Status: Published application
- Kind: A1
- Application number: 18/462,207
- Filed: 2023-09-06
- Published: 2024-08-01
- Earliest claimed: 2016-06-08
- Assignees: Precigen, Inc.
- Applicants: Precigen, Inc.
- Inventors: Rutul SHAH; Tim CHAN; Peter EMTAGE; Ramya YARLAGADDA
- Web page: https://patentgrep.com/patent/US20240254188A1

## CPC

- C07K 14/70503: {Immunoglobulin superfamily}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4205: {Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4}
- A61K 40/4211: {CD19 or B4}
- A61K 40/4224: {Molecules with a "CD" designation not provided for elsewhere}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70575: {NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 (NGF C07K14/48, TNF C07K14/525)}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C07K 14/71: for growth factors; for growth regulators
- C07K 16/2803: {against the immunoglobulin superfamily}
- C12N 5/0636: {T lymphocytes}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2239/29: Multispecific CARs
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C12N 2510/00: Genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.

## Claims

### Claim at position 1

1-13. (canceled)

### Claim 14

A vector comprising a backbone and a nucleic acid sequence encoding:
(a) a truncated epidermal growth factor receptor comprising a polypeptide having at least 90% identity with the amino acid sequence of SEQ ID NO: 32; and
(b) a chimeric antigen receptor (CAR) comprising: a CD33 antigen binding domain; a transmembrane domain; and an intercellular signaling domain.

### Claim 15

A vector comprising a backbone and a nucleic acid sequence encoding:
(a) a full length CD20, a truncated CD20 (CD20t-1), or a functional variant of CD20; and
(b) a chimeric antigen receptor (CAR) comprising: a CD33 antigen binding domain; a transmembrane domain; and an intercellular signaling domain.

### Claim 16 (depends on 14)

The vector of claim 14, wherein the vector is a lentivirus vector, a retroviral vector, or a non-viral vector.

### Claim 17

(canceled)

### Claim 18 (depends on 15)

The vector of claim 15, wherein the nucleic acid encodes a polypeptide having at least 90% identity with the amino acid sequence of SEQ ID NO: 36 or 56.

### Claim at position 7

19-22. (canceled)

### Claim 23 (depends on 14)

The vector of claim 14, further comprising an 22, wherein the promoter hEF1a1 promoter.

### Claim 24 (depends on 14)

The vector of claim 14, wherein the CD33 antigen binding domain comprises at least one of:
(a) a polypeptide having at least 90% identity with the amino acid sequence of SEQ ID NO: 8 (hM195scFv);
(b) a polypeptide having at least 90% identity with the amino acid sequence of SEQ ID NOs: 9 and 10 (M2H12);
(c) a polypeptide having at least 90% identity with the amino acid sequence of SEQ ID NOs: 11 and 12 (DRB2); and
(d) a polypeptide having at least 90% identity with the amino acid sequence of SEQ ID NOs: 14 and 15 (My9-6).

### Claim 25

(canceled)

### Claim 26 (depends on 14)

The vector of claim 14, wherein: (a) the stalk domain comprises a polypeptide having at least 90% identity with the amino acid sequence of SEQ ID NO: 22; (b) the costimulatory signaling domain comprises a polypeptide having at least 90% identity with the amino acid sequence of SEQ ID NO: 24 or 28; and (c) the CD3 zeta signaling domain comprises a polypeptide having at least 90% identity with the amino acid sequence of SEQ ID NO: 26.

### Claim at position 12

27-35. (canceled)

### Claim 36 (depends on 14)

An immune effector cell comprising the vector of claim 14.

### Claim at position 14

37-41. (canceled)

### Claim 42 (depends on 35, 36)

The immune effector cell of claim 36, any one of claims 35 41, wherein the cell is a T cell, a Natural Killer (NK) cell, a cytotoxic T lymphocyte (CTL), or a regulatory T cell.

### Claim 43

(canceled)

### Claim 44 (depends on 36)

A method for stimulating a T cell-mediated immune response to a target cell population or tissue in a human subject in need thereof, the method comprising administering to the human subject an effective amount of the cell of claim 36.

### Claim at position 18

45-52. (canceled)

### Claim 53 (depends on 14)

A system for expressing a CAR in an immune effector cell, the system comprising: (a) a recombinase or a nucleic acid encoding same; and (b) the vector of claim 14, wherein the vector comprises a recombination site.

### Claim at position 20

54-65. (canceled)

### Claim 66 (depends on 53)

A method of expressing a CAR in an immune effector cell comprising contacting the immune effector cell with the system of claim 53.

### Claim 67 (depends on 14)

A method of stimulating the proliferation and/or survival of engineered T-cells, the method comprising (a) transfecting cells obtained from a subject with (i) the vector of claim 14 and (ii) a vector encoding a transposase; and (b) producing a population of engineered CD33 CAR-expressing T-cells.

### Claim at position 23

68-73. (canceled)

### Claim 74

A vector comprising a backbone and a nucleic acid sequence encoding: (a) a cytokine; and (b) a chimeric antigen receptor comprising a CD33 antigen binding domain, a transmembrane domain, and an intracellular signaling domain.

### Claim 75

A composition comprising a cell expressing: (a) a truncated epidermal growth factor receptor; and (b) a chimeric antigen receptor comprising a CD33 antigen binding domain, a transmembrane domain, and an intracellular signaling domain.

### Claim 76 (depends on 75)

The composition of claim 75 further comprising a cytokine or a nucleic acid encoding the same.

### Claim 77 (depends on 36)

A method for treating a cancer in a subject in need thereof, the method comprising administering the immune effector cell of claim 36 to the subject.

### Claim 78 (depends on 14)

A composition comprising the vector of claim 14.

### Claim 79 (depends on 14)

A kit comprising the vector of claim 14.

### Claim 80 (depends on 14)

A method of stimulating the proliferation and/or survival of engineered T-cells, the method comprising transfecting cells obtained from a subject with the vector of claim 14.
